Global Diabetic Neuropathic Pain Drug Market Insights and Forecast to 2026

Global Diabetic Neuropathic Pain Drug Market Insights and Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Diabetic Neuropathic Pain Drug Product Introduction
1.2 Market Segments
1.3 Key Diabetic Neuropathic Pain Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type
1.4.2 AZD-5213
1.4.3 Clonidine Hydrochloride
1.4.4 Duloxetine Hydrochloride DR
1.4.5 E-52862
1.4.6 Filgrastim
1.4.7 GERPOOI
1.4.8 GRC-17536
1.4.9 Others
1.5 Market by Application
1.5.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Diabetic Neuropathic Pain Drug Market Size, Estimates and Forecasts
2.1.1 Global Diabetic Neuropathic Pain Drug Revenue 2015-2026
2.1.2 Global Diabetic Neuropathic Pain Drug Sales 2015-2026
2.2 Global Diabetic Neuropathic Pain Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Diabetic Neuropathic Pain Drug Competitor Landscape by Players
3.1 Diabetic Neuropathic Pain Drug Sales by Manufacturers
3.1.1 Diabetic Neuropathic Pain Drug Sales by Manufacturers (2015-2020)
3.1.2 Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Diabetic Neuropathic Pain Drug Revenue by Manufacturers
3.2.1 Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2015-2020)
3.2.2 Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Diabetic Neuropathic Pain Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Diabetic Neuropathic Pain Drug Revenue in 2019
3.2.5 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Diabetic Neuropathic Pain Drug Price by Manufacturers
3.4 Diabetic Neuropathic Pain Drug Manufacturing Base Distribution, Product Types
3.4.1 Diabetic Neuropathic Pain Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Diabetic Neuropathic Pain Drug Product Type
3.4.3 Date of International Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Diabetic Neuropathic Pain Drug Market Size by Type (2015-2020)
4.1.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2015-2020)
4.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2015-2020)
4.1.3 Diabetic Neuropathic Pain Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Type (2021-2026)
4.2.3 Diabetic Neuropathic Pain Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Diabetic Neuropathic Pain Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Diabetic Neuropathic Pain Drug Market Size by Application (2015-2020)
5.1.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2015-2020)
5.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2015-2020)
5.1.3 Diabetic Neuropathic Pain Drug Price by Application (2015-2020)
5.2 Diabetic Neuropathic Pain Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Diabetic Neuropathic Pain Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Diabetic Neuropathic Pain Drug by Country
6.1.1 North America Diabetic Neuropathic Pain Drug Sales by Country
6.1.2 North America Diabetic Neuropathic Pain Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
6.3 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Diabetic Neuropathic Pain Drug by Country
7.1.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
7.1.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
7.3 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Diabetic Neuropathic Pain Drug by Region
8.1.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region
8.1.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
8.3 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Diabetic Neuropathic Pain Drug by Country
9.1.1 Latin America Diabetic Neuropathic Pain Drug Sales by Country
9.1.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
9.3 Central & South America Diabetic Neuropathic Pain Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Diabetic Neuropathic Pain Drug by Country
10.1.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country
10.1.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
10.3 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Corporation Information
11.1.2 Astellas Pharma Inc. Description and Business Overview
11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
11.1.5 Astellas Pharma Inc. Related Developments
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Corporation Information
11.2.2 AstraZeneca Plc Description and Business Overview
11.2.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Products Offered
11.2.5 AstraZeneca Plc Related Developments
11.3 BioDelivery Sciences International, Inc.
11.3.1 BioDelivery Sciences International, Inc. Corporation Information
11.3.2 BioDelivery Sciences International, Inc. Description and Business Overview
11.3.3 BioDelivery Sciences International, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Products Offered
11.3.5 BioDelivery Sciences International, Inc. Related Developments
11.4 Boehringer Ingelheim GmbH
11.4.1 Boehringer Ingelheim GmbH Corporation Information
11.4.2 Boehringer Ingelheim GmbH Description and Business Overview
11.4.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Products Offered
11.4.5 Boehringer Ingelheim GmbH Related Developments
11.5 Daiichi Sankyo Company, Limited
11.5.1 Daiichi Sankyo Company, Limited Corporation Information
11.5.2 Daiichi Sankyo Company, Limited Description and Business Overview
11.5.3 Daiichi Sankyo Company, Limited Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Products Offered
11.5.5 Daiichi Sankyo Company, Limited Related Developments
11.6 Dong-A Socio Group
11.6.1 Dong-A Socio Group Corporation Information
11.6.2 Dong-A Socio Group Description and Business Overview
11.6.3 Dong-A Socio Group Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Products Offered
11.6.5 Dong-A Socio Group Related Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Corporation Information
11.7.2 Eli Lilly and Company Description and Business Overview
11.7.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Products Offered
11.7.5 Eli Lilly and Company Related Developments
11.8 Glenmark Pharmaceuticals Ltd.
11.8.1 Glenmark Pharmaceuticals Ltd. Corporation Information
11.8.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
11.8.3 Glenmark Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Products Offered
11.8.5 Glenmark Pharmaceuticals Ltd. Related Developments
11.9 Hydra Biosciences, Inc.
11.9.1 Hydra Biosciences, Inc. Corporation Information
11.9.2 Hydra Biosciences, Inc. Description and Business Overview
11.9.3 Hydra Biosciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Products Offered
11.9.5 Hydra Biosciences, Inc. Related Developments
11.10 Immune Pharmaceuticals Inc.
11.10.1 Immune Pharmaceuticals Inc. Corporation Information
11.10.2 Immune Pharmaceuticals Inc. Description and Business Overview
11.10.3 Immune Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Products Offered
11.10.5 Immune Pharmaceuticals Inc. Related Developments
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Corporation Information
11.1.2 Astellas Pharma Inc. Description and Business Overview
11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
11.1.5 Astellas Pharma Inc. Related Developments
11.12 Lohocla Research Corporation
11.12.1 Lohocla Research Corporation Corporation Information
11.12.2 Lohocla Research Corporation Description and Business Overview
11.12.3 Lohocla Research Corporation Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Lohocla Research Corporation Products Offered
11.12.5 Lohocla Research Corporation Related Developments
11.13 Mertiva AB
11.13.1 Mertiva AB Corporation Information
11.13.2 Mertiva AB Description and Business Overview
11.13.3 Mertiva AB Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Mertiva AB Products Offered
11.13.5 Mertiva AB Related Developments
11.14 Novaremed
11.14.1 Novaremed Corporation Information
11.14.2 Novaremed Description and Business Overview
11.14.3 Novaremed Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Novaremed Products Offered
11.14.5 Novaremed Related Developments
11.15 Pharmaleads
11.15.1 Pharmaleads Corporation Information
11.15.2 Pharmaleads Description and Business Overview
11.15.3 Pharmaleads Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Pharmaleads Products Offered
11.15.5 Pharmaleads Related Developments
11.16 RAPID Pharmaceuticals AG
11.16.1 RAPID Pharmaceuticals AG Corporation Information
11.16.2 RAPID Pharmaceuticals AG Description and Business Overview
11.16.3 RAPID Pharmaceuticals AG Sales, Revenue and Gross Margin (2015-2020)
11.16.4 RAPID Pharmaceuticals AG Products Offered
11.16.5 RAPID Pharmaceuticals AG Related Developments
11.17 Relmada Therapeutics, Inc.
11.17.1 Relmada Therapeutics, Inc. Corporation Information
11.17.2 Relmada Therapeutics, Inc. Description and Business Overview
11.17.3 Relmada Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Relmada Therapeutics, Inc. Products Offered
11.17.5 Relmada Therapeutics, Inc. Related Developments
11.18 Sphaera Pharma Pvt. Ltd.
11.18.1 Sphaera Pharma Pvt. Ltd. Corporation Information
11.18.2 Sphaera Pharma Pvt. Ltd. Description and Business Overview
11.18.3 Sphaera Pharma Pvt. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Sphaera Pharma Pvt. Ltd. Products Offered
11.18.5 Sphaera Pharma Pvt. Ltd. Related Developments
11.19 Theravasc, Inc.
11.19.1 Theravasc, Inc. Corporation Information
11.19.2 Theravasc, Inc. Description and Business Overview
11.19.3 Theravasc, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Theravasc, Inc. Products Offered
11.19.5 Theravasc, Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Diabetic Neuropathic Pain Drug Market Estimates and Projections by Region
12.1.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Regions 2021-2026
12.2 North America Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
12.2.1 North America: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
12.2.2 North America: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
12.2.3 North America: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
12.3.2 Europe: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Diabetic Neuropathic Pain Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Diabetic Neuropathic Pain Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Diabetic Neuropathic Pain Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Diabetic Neuropathic Pain Drug Market Segments
Table 2. Ranking of Global Top Diabetic Neuropathic Pain Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AZD-5213
Table 5. Major Manufacturers of Clonidine Hydrochloride
Table 6. Major Manufacturers of Duloxetine Hydrochloride DR
Table 7. Major Manufacturers of E-52862
Table 8. Major Manufacturers of Filgrastim
Table 9. Major Manufacturers of GERPOOI
Table 10. Major Manufacturers of GRC-17536
Table 11. Major Manufacturers of Others
Table 12. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 13. Global Diabetic Neuropathic Pain Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 14. Global Diabetic Neuropathic Pain Drug Sales by Regions 2015-2020 (K Pcs)
Table 15. Global Diabetic Neuropathic Pain Drug Sales Market Share by Regions (2015-2020)
Table 16. Global Diabetic Neuropathic Pain Drug Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Diabetic Neuropathic Pain Drug Sales Share by Manufacturers (2015-2020)
Table 19. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2019)
Table 21. Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Diabetic Neuropathic Pain Drug Price (2015-2020) (USD/Pcs)
Table 24. Diabetic Neuropathic Pain Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Diabetic Neuropathic Pain Drug Product Type
Table 26. Date of International Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 29. Global Diabetic Neuropathic Pain Drug Sales Share by Type (2015-2020)
Table 30. Global Diabetic Neuropathic Pain Drug Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2015-2020)
Table 32. Diabetic Neuropathic Pain Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 34. Global Diabetic Neuropathic Pain Drug Sales Share by Application (2015-2020)
Table 35. North America Diabetic Neuropathic Pain Drug Sales by Country (2015-2020) (K Pcs)
Table 36. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2015-2020)
Table 37. North America Diabetic Neuropathic Pain Drug Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2015-2020)
Table 39. North America Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 40. North America Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 41. North America Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 42. North America Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 43. Europe Diabetic Neuropathic Pain Drug Sales by Country (2015-2020) (K Pcs)
Table 44. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country (2015-2020)
Table 45. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2015-2020)
Table 47. Europe Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 48. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 50. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2015-2020) (K Pcs)
Table 52. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 56. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 58. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 59. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2015-2020) (K Pcs)
Table 60. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Diabetic Neuropathic Pain Drug Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2015-2020)
Table 63. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 64. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 65. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 66. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2015-2020) (K Pcs)
Table 68. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2015-2020) (K Pcs)
Table 72. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2015-2020) (K Pcs)
Table 74. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 75. Astellas Pharma Inc. Corporation Information
Table 76. Astellas Pharma Inc. Description and Major Businesses
Table 77. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Astellas Pharma Inc. Product
Table 79. Astellas Pharma Inc. Recent Development
Table 80. AstraZeneca Plc Corporation Information
Table 81. AstraZeneca Plc Description and Major Businesses
Table 82. AstraZeneca Plc Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. AstraZeneca Plc Product
Table 84. AstraZeneca Plc Recent Development
Table 85. BioDelivery Sciences International, Inc. Corporation Information
Table 86. BioDelivery Sciences International, Inc. Description and Major Businesses
Table 87. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. BioDelivery Sciences International, Inc. Product
Table 89. BioDelivery Sciences International, Inc. Recent Development
Table 90. Boehringer Ingelheim GmbH Corporation Information
Table 91. Boehringer Ingelheim GmbH Description and Major Businesses
Table 92. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Boehringer Ingelheim GmbH Product
Table 94. Boehringer Ingelheim GmbH Recent Development
Table 95. Daiichi Sankyo Company, Limited Corporation Information
Table 96. Daiichi Sankyo Company, Limited Description and Major Businesses
Table 97. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Daiichi Sankyo Company, Limited Product
Table 99. Daiichi Sankyo Company, Limited Recent Development
Table 100. Dong-A Socio Group Corporation Information
Table 101. Dong-A Socio Group Description and Major Businesses
Table 102. Dong-A Socio Group Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Dong-A Socio Group Product
Table 104. Dong-A Socio Group Recent Development
Table 105. Eli Lilly and Company Corporation Information
Table 106. Eli Lilly and Company Description and Major Businesses
Table 107. Eli Lilly and Company Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Eli Lilly and Company Product
Table 109. Eli Lilly and Company Recent Development
Table 110. Glenmark Pharmaceuticals Ltd. Corporation Information
Table 111. Glenmark Pharmaceuticals Ltd. Description and Major Businesses
Table 112. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Glenmark Pharmaceuticals Ltd. Product
Table 114. Glenmark Pharmaceuticals Ltd. Recent Development
Table 115. Hydra Biosciences, Inc. Corporation Information
Table 116. Hydra Biosciences, Inc. Description and Major Businesses
Table 117. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Hydra Biosciences, Inc. Product
Table 119. Hydra Biosciences, Inc. Recent Development
Table 120. Immune Pharmaceuticals Inc. Corporation Information
Table 121. Immune Pharmaceuticals Inc. Description and Major Businesses
Table 122. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Immune Pharmaceuticals Inc. Product
Table 124. Immune Pharmaceuticals Inc. Recent Development
Table 125. Laboratorios Del Dr. Esteve S.A. Corporation Information
Table 126. Laboratorios Del Dr. Esteve S.A. Description and Major Businesses
Table 127. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Laboratorios Del Dr. Esteve S.A. Product
Table 129. Laboratorios Del Dr. Esteve S.A. Recent Development
Table 130. Lohocla Research Corporation Corporation Information
Table 131. Lohocla Research Corporation Description and Major Businesses
Table 132. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Lohocla Research Corporation Product
Table 134. Lohocla Research Corporation Recent Development
Table 135. Mertiva AB Corporation Information
Table 136. Mertiva AB Description and Major Businesses
Table 137. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Mertiva AB Product
Table 139. Mertiva AB Recent Development
Table 140. Novaremed Corporation Information
Table 141. Novaremed Description and Major Businesses
Table 142. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Novaremed Product
Table 144. Novaremed Recent Development
Table 145. Pharmaleads Corporation Information
Table 146. Pharmaleads Description and Major Businesses
Table 147. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Pharmaleads Product
Table 149. Pharmaleads Recent Development
Table 150. RAPID Pharmaceuticals AG Corporation Information
Table 151. RAPID Pharmaceuticals AG Description and Major Businesses
Table 152. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. RAPID Pharmaceuticals AG Product
Table 154. RAPID Pharmaceuticals AG Recent Development
Table 155. Relmada Therapeutics, Inc. Corporation Information
Table 156. Relmada Therapeutics, Inc. Description and Major Businesses
Table 157. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 158. Relmada Therapeutics, Inc. Product
Table 159. Relmada Therapeutics, Inc. Recent Development
Table 160. Sphaera Pharma Pvt. Ltd. Corporation Information
Table 161. Sphaera Pharma Pvt. Ltd. Description and Major Businesses
Table 162. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 163. Sphaera Pharma Pvt. Ltd. Product
Table 164. Sphaera Pharma Pvt. Ltd. Recent Development
Table 165. Theravasc, Inc. Corporation Information
Table 166. Theravasc, Inc. Description and Major Businesses
Table 167. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 168. Theravasc, Inc. Product
Table 169. Theravasc, Inc. Recent Development
Table 170. Global Diabetic Neuropathic Pain Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 171. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Regions (2021-2026)
Table 172. Global Diabetic Neuropathic Pain Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 173. Global Diabetic Neuropathic Pain Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 174. North America: Diabetic Neuropathic Pain Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 175. North America: Diabetic Neuropathic Pain Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 176. Europe: Diabetic Neuropathic Pain Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 177. Europe: Diabetic Neuropathic Pain Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 178. Asia Pacific: Diabetic Neuropathic Pain Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 179. Asia Pacific: Diabetic Neuropathic Pain Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 180. Latin America: Diabetic Neuropathic Pain Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 181. Latin America: Diabetic Neuropathic Pain Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 182. Middle East and Africa: Diabetic Neuropathic Pain Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 183. Middle East and Africa: Diabetic Neuropathic Pain Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 184. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 185. Key Challenges
Table 186. Market Risks
Table 187. Main Points Interviewed from Key Diabetic Neuropathic Pain Drug Players
Table 188. Diabetic Neuropathic Pain Drug Customers List
Table 189. Diabetic Neuropathic Pain Drug Distributors List
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetic Neuropathic Pain Drug Product Picture
Figure 2. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2020 & 2026
Figure 3. AZD-5213 Product Picture
Figure 4. Clonidine Hydrochloride Product Picture
Figure 5. Duloxetine Hydrochloride DR Product Picture
Figure 6. E-52862 Product Picture
Figure 7. Filgrastim Product Picture
Figure 8. GERPOOI Product Picture
Figure 9. GRC-17536 Product Picture
Figure 10. Others Product Picture
Figure 11. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2020 & 2026
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Diabetic Neuropathic Pain Drug Report Years Considered
Figure 16. Global Diabetic Neuropathic Pain Drug Market Size 2015-2026 (US$ Million)
Figure 17. Global Diabetic Neuropathic Pain Drug Sales 2015-2026 (K Pcs)
Figure 18. Global Diabetic Neuropathic Pain Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2015-2020)
Figure 20. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2019
Figure 21. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2015-2020)
Figure 22. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region in 2019
Figure 23. Global Diabetic Neur

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs